Genetic Technologies updates patent program, grants license


Genetic Technologies (GENE) grants a license to Bio-Reference Labs (BRLI) — terms are confidential "as is typical in such cases."

GENE is also "pleased to report" that it is "actively pursuing its patent assertion program and there are now "several significant cases" pending in Delaware "including cases against PFE, BMY, and Merial." (PR)

GENE +13% premarket

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs